Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Clinical characteristics of the patients with RA from the first and second replication collections

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

  First replication Second replication
Features All patients Infliximab Adalimumab Infliximab
Patients, number (%) 404 199 (49.3) 205 (50.7) 386
Female (%) 77.2 77.9 76.6 89.1
Age at diagnosis, median (IQR) 46 (34 to 53) 42 (33 to 51) 48 (36 to 56) 44 (35 to 51)
Diagnosis to anti-TNF, median (IQR) 10 (5 to 17) 11 (6 to 18) 9 (4 to 17) 8 (4 to 15)
ACPA, %a 77.4 79.4 75.5 60.9
Erosive arthritis, %a 58.2 65.0 51.1 77.6
Smoking, %a 56.6 56.8 56.3 26.1
Concomitant DMARDs (%)a 100 100 100 96.4
Baseline HAQ, median (IQR) 2.0 (1.6 to 2.4) 2.0 (1.8 to 2.5) 2.0 (1.5 to 2.3) 1.9 (1.4 to 2.3)
DAS28, (mean ± SD)     
 baseline 6.5 ± 1.1 6.7 ± 1.0 6.3 ± 1.1 6.1 ± 1.2
 six months 4.1 ± 1.3 4.3 ± 1.3 3.8 ± 1.2 4.1 ± 1.5
six months EULAR response, %     
 responder 21.3 17.1 25.4 29.2
 moderate 69.6 73.4 65.9 46.9
 no-responder 9.2 9.5 8.8 24.0
  1. aData from <85% of patients: in the first replication (310 patients for concomitant DMARDs); in the second replication (196 patients for erosive arthritis; 174 for ACPA; 115 patients for smoking). ACPA, anti-citrullinated peptide antibodies; ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; DMARDs, disease modifying antirheumatic drugs; EULAR, European League against Rheumatism; HAQ, Health Assessment Questionnaire; INX, infliximab; IQR, interquartile range; RA, rheumatoid arthritis; SD, standard deviation.